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in Mice Immunized with a Recombinant RSV G Protein Fragment
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The relative immunopathogenic potential of a recombinant fusion protein incorporating residues 130–230 of respiratory
syncytial virus (RSV-A) G protein (BBG2Na), formalin-inactivated RSV-A (FI-RSV), and phosphate-buffered saline (PBS) was
investigated in mice after immunization and RSV challenge. FI-RSV priming resulted in massive infiltration of B cells and
activated CD41 and CD81 T lymphocytes in mediastinal lymph nodes (MLN) and lungs, where eosinophilia and elevated
IFN-g, IL-2, -4, -5, -10, and -13 mRNA transcripts were also detected. PBS-primed mice showed only elevated pulmonary IL-2
and IFN-g mRNAs, while an activated CD81 T cell peak was detected in MLN and lungs. Cell infiltration also occurred in MLN
of BBG2Na-immunized mice. However, there was no evidence of T cell, B cell, or granulocyte infiltration or activation in lungs,
while transient transcription of Th1-type cytokine genes was evident. The absence of pulmonary infiltration is unlikely due to
insufficient viral antigen. Thus, this recombinant fusion RSV G fragment does not prime for adverse pulmonary immuno-
pathologic responses. © 1999 Academic Press
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(INTRODUCTION
Respiratory syncytial virus (RSV) is a major respiratory
athogen responsible for severe pulmonary disease in
ery young children, immunodeficient patients, and the
lderly (Collins et al., 1996). First infection generally oc-
urs despite the presence of maternal antibodies and
epresents the most common cause of infant hospital-
zation. Furthermore, antiviral immunity is poorly induced
nd reinfections are frequent throughout life.
Despite the clinical and economic importance of this
nfection, efforts to develop an efficacious RSV vaccine
ave been unsuccessful to date (Anderson and Heilman,
995). Live attenuated, inactivated, and subunit vaccine
andidates failed to protect and/or demonstrated poten-
ial to enhance lung pathology upon subsequent RSV
nfection (for review see Murphy et al., 1994). Indeed,
SV-enhanced disease was first encountered in the
960s during the clinical evaluation of a formalin-inacti-
ated whole RSV preparation (FI-RSV). This vaccine prep-
ration not only failed to protect the immunized children
ut also enhanced the rate of hospitalization after sub-
equent RSV infection and was associated with two
eaths (Kim et al., 1969).
Mice and cotton rats are semipermissive to RSV infection
nd also show enhanced pathology upon RSV challenge
ollowing immunization with FI-RSV (Prince et al., 1986;
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (33) 450.35.35.90. E-mail: helene.plotnicky@pierre-fabre.Rom; ultan.power@pierre-fabre.com.
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128aux-Peretz et al., 1992). In these animal models, RSV major
urface glycoproteins F (implicated in viral fusion and syn-
ytium formation) and G (attachment protein) are the prin-
ipal protagonists of protective immune responses (Con-
ors et al., 1991; Routledge et al., 1988). In contrast to the F
rotein, G protein is characterized by a particularly high
ntigenic and genetic variability between and within RSV
ubgroups (Johnson and Collins, 1988; Cane et al., 1991).
his suggests the influence of high environmental and/or
mmunologic pressure. However, both F and G proteins
ere implicated in adverse anti-RSV responses. The most
evere pulmonary disease, characterized by lymphocyte
nfiltration and eosinophilia, resulted from prior immuniza-
ion with G protein and was associated with the induction/
ecall of a strong Th2-type anti-RSV T cell response upon
iral challenge (Vaux-Pertz et al., 1992; Alwan et al., 1994;
urphy et al., 1990; Hancock et al., 1996). These immuno-
ogical events are also induced in the FI-RSV associated
ung pathogenesis (Waris et al., 1996; Connors et al., 1994).
nterestingly, the G protein has a unique structure with over
0% of its molecular weight estimated to be carbohydrate,
he majority of which is O-linked sugars (Wertz et al., 1985).
t was hypothesized that this exceptional rate of glycosyla-
ion may play a role in the induction of a Th2-type response
nd may account for the immunopathologic potential of this
rotein (Anderson and Heilman, 1995).
Recently, we evaluated the protective efficacy of an
SV G protein fragment (G2Na), which is produced in
scherichia coli as a recombinant fusion protein
BBG2Na). BBG2Na comprises residues 130–230 of
SV-A G protein (G2Na) fused to BB, an albumin binding
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129ABSENCE OF IMMUNOPATHOLOGY WITH RSV G FRAGMENTomain of streptococcal protein G with carrier protein-
elated properties (Libon et al., 1999; Makrides et al.,
996; Nygren et al., 1991). G2Na includes a conserved
ubgroup A-specific protective epitope (residues 174–
87) (Trudel et al., 1991) and a stretch of amino acid
esidues that are completely conserved in all known
uman RSV isolates (residues 164–176) (Collins et al.,
996). Accordingly, BBG2Na was shown to induce high
evels of antibodies in mice reactive with prototype sub-
roup A and B RSV strains, as well as a rapid, potent, and
ong-lasting protection against RSV-A infection. In addi-
ion, protective efficacy was also demonstrated in cotton
ats against both RSV-A and -B (Power et al., 1997).
A previous evaluation of serum cytokine profiles in mice
emonstrated that although BBG2Na induces a predomi-
ant Th2-type T cell response upon immunization, no pro-
uction of IL-4, IL-5, or IgE is detected after live RSV chal-
enge. Thus, the Th2-type memory T cells are not recalled in
he periphery following challenge (Corvaia et al., 1997). The
im of the current study was to investigate the effect of RSV
hallenge in the lower respiratory tract of BBG2Na-immu-
ized mice. For this purpose, we analyzed the fine cellular
nd molecular events occurring in mediastinal lymph
odes (MLN) and lung tissues after RSV-A challenge. Our
ata clearly demonstrate that, in contrast to FI-RSV, this
ecombinant RSV G protein fragment does not prime for
h2-type RSV immunopathologic responses.
RESULTS
ffects of priming and RSV challenge on nucleated
ell infiltration in MLN and lungs
To determine the comparative effects of priming with
FIG. 1. Nucleated cell infiltration in MLN and lungs following RSV c
BG2Na (—F—), or FI-RSV (– z n– z ) in Alhydrogel and challenged i.n
ells were isolated from MLN and lungs, enumerated, and compared to
f nucleated cells in MLN (A) and lungs (B) were calculated from grouarious antigens on postchallenge cellular responses, fhe kinetics of nucleated cell populations infiltrating MLN
nd lung tissues of BBG2Na-, PBS-, and FI-RSV-immu-
ized mice were analyzed after intranasal (i.n.) challenge
ith 105 TCID50 RSV-A. The numbers of nucleated cells
ncreased rapidly from day 2 postchallenge in the MLN
nd lungs of FI-RSV-immunized mice and peaked at day
for MLN and at day 7 for lungs, with mean cell numbers
f 21 6 6.1 3 106 and 34.7 6 2.6 3 106, respectively
Figs. 1A and 1B). Extensive and comparable cell infiltra-
ion postchallenge was evident in PBS- and BBG2Na-
mmunized mice in the MLN compared with naive un-
hallenged mice (approximately 8 3 106 and 2 3 106,
espectively), but not in the lungs. However, this MLN
nfiltration was significantly reduced relative to the FI-
SV-primed mice.
Flow cytometric analysis of the isolated cells based on
heir forward- and side-scatter distribution demonstrated
hat lymphocytes constituted the principal nucleated cell
opulation present in MLN of all groups and in the lungs
f naive unchallenged mice (not shown). This was also
he case for BBG2Na- and PBS-immunized mice after
SV-A challenge. In contrast, a significant population of
arge granular cells was also evident in the lungs of mice
mmunized with FI-RSV, representing 30 to 50% of the
ucleated cell lung infiltrate between days 5 and 9 post-
hallenge (not shown). Sorting of cells in the large gran-
lar cell gate from six or seven animals per group,
ollowed by May-Gru¨nwald Giemsa staining and light
icroscopic examination, revealed that the recovered
ells comprised 63 6 7% eosinophils in FI-RSV-immu-
ized/challenged mice, compared with less than 8% in
he other groups. The total number of eosinophils infil-
rating the lungs was subsequently extrapolated as a
e. BALB/c mice were immunized three times i.p. with PBS (——),
SV-A. They were sacrificed from day 2 to day 14 thereafter. Nucleated
rom naive unchallenged mice (. . .n. . .). Mean values 6 SD of numbers
to 12 mice for each time point.halleng
. with R
cells function of the total number of nucleated cells isolated
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130 PLOTNICKY-GILQUIN ET AL.rom the corresponding lungs. As represented in Fig. 2A,
ignificant lung eosinophilia was observed in the FI-RSV-
-immunized/RSV-A-challenged group, but not in the
ther groups.
Consistent with these data, the number of lung RB6-
C51 cells (granulocytes) at day 5 postchallenge was 20
o 30 times higher in the FI-RSV animals than in the other
roups (Fig. 2B). This population peaked at day 7 and
ould still be detected at day 14 in some animals. In
omparison, and in agreement with previous histologic
tudies of mouse lungs undergoing primary RSV infec-
ion (Anderson et al., 1990), PBS-immunized animals
emonstrated a small increase in RB6-8C51 cells at late
ime points postchallenge (days 12 and 14). No modifi-
ation was observed in the BBG2Na group, even after a
hallenge dose of 106 TCID50 of RSV-A (not shown), in
hich granulocyte populations always remained similar
o those of naive unchallenged mice.
ffects of priming and RSV challenge on lymphocyte
opulations
Both B (CD45R-B2201) and T (CD41 and CD81) lym-
hocytes were significantly increased postchallenge in
LN and lungs of mice immunized with FI-RSV (Figs. 3,
, and 5). At the peak of cell infiltration (days 5 and 7
ostchallenge), B and T lymphocyte populations in the
LN were more than 4 and 2 times more numerous,
FIG. 2. Infiltration of granulocyte cells in lung tissues of FI-RSV-immu
BS (——), BBG2Na (—F—), or FI-RSV (– z n– z ) in Alhydrogel an
igestion of the lung tissues and enumerated. (A) Large granular cells
icroscopy after staining with May-Gru¨nwald Giemsa and extrapolated
umbers of eosinophils 6 SD were calculated for groups of 6 to 8 mice
solated from days 2 to 14 postchallenge were stained with antibody
liminated by gating on forward and side scatter. The percentage of sta
umbers of granulocyte cells 6 SD were calculated for groups of 5
nchallenged mice per time point (. . .n. . .).espectively, than in the other groups (Figs. 3A, 4A, and 5C, P , 0.05). In the MLN of FI-RSV-primed mice, ex-
ression of early activation marker CD69 increased rap-
dly on CD41 and CD81 T cells and was maintained for
t least 14 days postchallenge (Figs. 4B and 4D), indi-
ating the induction of a strong cellular response of both
hese T lymphocyte subsets after RSV challenge. Activa-
ion of T cells was also observed in MLN of the PBS
roup but it was restricted to CD81 T cells at early time
oints. In contrast, although total numbers of
D45RB2201, CD41, and CD81 cells increased in
BG2Na-immunized mice in a manner comparable to the
BS group (Figs. 3A, 4A, and 4C), there was no evidence
f T cell activation in the MLN (Figs. 4B and 4D), sug-
esting that RSV challenge in this group stimulated only
B cell response.
As evident in the MLN, intense B and T cell infiltration
nd activation occurred in the lungs of FI-RSV-immu-
ized/challenged mice (Figs. 3B and 5). CD41 and CD81
cells were two and five times as numerous, respec-
ively, as in the lungs of naive unchallenged mice. More
han 95% of the cells were TCRab1 (data not shown),
oncordant with the phenotype of pulmonary T cells
nduced by RSV infection (Openshaw, 1991). Increased
xpression of CD69 was evident for more than 30% of the
D41 and CD81 cells on days 7 and 9, respectively
Figs. 5B and 5D). A similar percentage of CD69hi1
D81 T cells was also observed in the PBS group at day
mice after RSV-A infection. Mice were immunized three times i.p. with
enged i.n. with RSV-A. Infiltrating cells were isolated upon enzymatic
rted by FACS. The percentage of eosinophils was determined by light
l numbers as a function of total nucleated infiltrating cell counts. Mean
.05 calculated by t test using null hypothesis. (B) Lung infiltrating cells
5 and analyzed by flow cytometry after dead cells and debris were
ells was extrapolated to total numbers as indicated above. Mean total
nimals for each time point and compared with those from 10 naivenized
d chall
were so
to tota
. *P , 0
RB6-8C
ined c
to 11 a, consistent with the MLN data and confirming the
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131ABSENCE OF IMMUNOPATHOLOGY WITH RSV G FRAGMENTnduction of a strong CD81 T cell response. Furthermore,
onsistent with previous observations (Anderson et al.,
990; Taylor et al., 1985), a significant increase in the total
umber of pulmonary CD81 T cells was evident in the
atter group on days 7 and 9 postchallenge compared
ith naive unchallenged controls (Fig. 5C, P , 0.05).
nterestingly, 5 to 10% of CD41 T cells from PBS immu-
ized mice were also activated, indicating that RSV-A
nfection induced a local, albeit relatively low, CD41 T
ell response. These patterns of T lymphocyte activation
ere confirmed by the enhanced expression of LFA-1
data not shown).
No such increase or activation in lymphocyte subsets
as detected in pulmonary infiltrating cells of BBG2Na-
mmunized mice. The ratios of total numbers of
D41CD69hi1 to CD81CD69hi1 cells in these mice re-
ained comparable to those of naive unchallenged con-
rols during the 2 weeks following RSV-A challenge (approx-
mately 2:1). These ratios were reduced in PBS-immunized
ice (1:1.5), reflecting the predominance of activated CD81
cells. In contrast, they were approximately 10 times
reater (23:1, P , 0.05) in the FI-RSV group in which acti-
ated CD41 T cells were strikingly predominant at day 5
ompared with activated CD81 T cells. Thus, these data
learly demonstrate the absence of immunopathologic T
ell responses in lung tissues of BBG2Na-immunized mice,
n stark contrast to FI-RSV-immunized animals.
ffects of priming and RSV challenge on cytokine
RNA profiles
A characteristic Th2-type cytokine profile was previ-
FIG. 3. Kinetics of B cell infiltration in MLN and lungs after RSV ch
—F—), or FI-RSV (– z n– z ) in Alhydrogel and challenged i.n. with RSV-
nti-CD45RB220 antibody, and analyzed by flow cytometry after gating
nd lungs (B) were calculated from groups of 5 to 12 mice for each tim
oint (. . .n. . .).usly demonstrated in FI-RSV-immunized mice undergo- ong an immunopathologic reaction to RSV challenge,
hile a primary anti-RSV response was associated
ainly with the Th1-type cytokine profile (Graham et al.,
993; Hussell et al., 1996). We therefore determined
hether the massive eosinophil and lymphocyte infiltra-
ion observed in lungs of FI-RSV-immunized/challenged
ice, in contrast to BBG2Na-immunized/challenged
ice, also reflected major differences in the cytokine
xpression among the various groups. For this purpose,
e assessed representative Th1 and Th2 cytokine
RNA changes upon RSV-A challenge in pulmonary lym-
hocytes by a sensitive and specific semiquantitative
T-PCR ELISA technique (Janezic et al., 1995). The data
re presented as the ratio of the OD405nm for the cytokine
RNA relative to the OD405nm for b-actin mRNA.
The primary anti-RSV response developed in PBS-
mmunized animals was associated with increased ex-
ression of IL-2 and INF-g mRNA (Figs. 6A and 6B).
essenger RNA levels for these Th1-type cytokines
eaked at day 5, being 6 and 11.5 times greater, respec-
ively, than levels in naive unchallenged controls (P ,
.05). Subsequently, the levels decreased progressively
ntil day 14 postchallenge. The postchallenge kinetics of
L-2 mRNA expression in lung infiltrating cells from
BG2Na- and PBS-immunized mice paralleled one an-
ther during the first week, although the latter group
emonstrated slightly higher levels. These results are
onsistent with a Th1-type cellular response in the lungs
f the implicated mice (Hussell et al., 1996). However, at
ater time points, mean IL-2 mRNA expression in
BG2Na-immunized mice decreased to baseline levels
. Mice were immunized three times i.p. with PBS (——), BBG2Na
rating cells from MLN and lung tissues were enumerated, stained with
ard and side scatter. Mean total numbers of B cells 6 SD in MLN (A)
and compared with those from 7–8 naive unchallenged mice per timeallenge
A. Infilt
on forw
e pointbserved in naive unchallenged mice. In lung infiltrating
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132 PLOTNICKY-GILQUIN ET AL.ells from FI-RSV-immunized animals, IL-2 mRNA accu-
ulated until day 9 postchallenge (P , 0.05). IFN-g
RNA levels in BBG2Na-immunized mouse lung cell
nfiltrates were never statistically different from those of
aive mice. In contrast, they were strongly enhanced by
ay 5 in infiltrating cells from both PBS- and FI-RSV-
mmunized mice. Unlike PBS-immunized mice, however,
FN-g mRNA levels in the latter mice remained stable
uring the following 9 days (P , 0.05).
For Th2-type cytokines, including IL-4, IL-5, IL-10, and
L-13, markedly elevated levels of mRNA were observed
lmost exclusively in the lung infiltrating cells of FI-RSV-
mmunized animals (Figs. 6C, 6D, 6E, and 6F). Mean IL-4
nd IL-13 mRNA levels peaked at day 5 (P , 0.05), being 20
FIG. 4. Activated CD4 and CD8 T lymphocytes in MLN of mice afte
BG2Na (—F—), or FI-RSV (– z n– z ) in Alhydrogel and challenged
luorescent antibody combinations specific for CD4, CD8, and CD69, an
otal numbers of CD41 (A) and CD81 (C) and percentages of activated
f 5 to 12 mice for each time point and compared with those from 7–8nd 60 times higher than those measured in any other eroup. Elevated IL-5 and IL-10 mRNA expression was al-
eady evident at day 2 postchallenge (being 15 and 10 times
igher, respectively, than those of any other group, P ,
.05) and remained stable until day 5. Subsequently, mRNA
xpression gradually diminished, such that by day 14, levels
lose to baseline were observed for all Th2-type cytokines.
n contrast, only low levels of Th2-type cytokine mRNAs
ere detected in the BBG2Na and PBS groups, which were
n general similar to cytokine expression levels in the lungs
f naive unchallenged mice. One exception was the ap-
earance of a peak of IL-10 at day 9 postchallenge in
BS-immunized mice (Fig. 6E, P , 0.05). Slightly elevated
L-4 and IL-13 mRNA expression was also observed on day
in these animals but was not statistically different from
challenge. Mice were immunized three times i.p. with PBS (——),
th RSV-A. Infiltrating cells from MLN were enumerated, stained with
yzed by flow cytometry after gating on forward and side scatter. Mean
hi1) CD4 (B) and CD8 (D) T cells 6 SD were calculated from groups
unchallenged mice per time point (. . .n. . .).r RSV
i.n. wi
d anal
(CD69
naivexpression in naive mice. These data are consistent with
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133ABSENCE OF IMMUNOPATHOLOGY WITH RSV G FRAGMENThe lung cell infiltration kinetics reported above. Further-
ore, they confirm that, in contrast to FI-RSV, Th2-type
ulmonary immunopathologic responses do not occur
pon live viral challenge of BBG2Na-primed mice.
ffects of immunization on the presence of viral
RNA transcripts
Previous work from our laboratory demonstrated
hat at 24 h following intranasal RSV challenge, no or
inimal detectable tissue culture infectious virus
ould be found in lungs of mice immunized three times
ith 20 mg BBG2Na (Power et al., 1997). Therefore, the
ossibility existed that the rapid sterilizing protective
fficacy of BBG2Na may be responsible for the ab-
FIG. 5. Activated CD4 and CD8 T lymphocytes in lung tissues of mice
BG2Na (—F—), or FI-RSV (– z n– z ) in Alhydrogel and challenged i.n.
luorescent antibody combinations specific for CD4, CD8, and CD69, an
otal numbers of CD41 (A) and CD81 (C) and percentages of activated
f 5 to 12 mice for each time point and compared with those from 7–8ence of enhanced immunopathology upon RSV-A thallenge. The persistence of viral transcripts in the
bsence of detectable infectious virions was previ-
usly demonstrated in RSV and vesicular stomatitis
irus animal models (Barrera and Letchworth, 1996;
egele et al., 1994). Thus, we analyzed RSV G mRNA
ranscripts by RT-PCR ELISA in the lungs of BBG2Na-,
I-RSV-, and PBS-immunized mice 2 days after chal-
enge. Not surprisingly, high virus-specific mRNA lev-
ls were detected in lung tissues of PBS-immunized
ice, indicating the occurrence of viral transcription in
he pulmonary tissues (Fig. 7). Viral mRNA was also
etected in lung tissues from BBG2Na- and FI-RSV-
mmunized animals, albeit at lower levels. Average
RNA levels were much lower in the lungs of FI-RSV-
SV challenge. Mice were immunized three times i.p. with PBS (——),
V-A. Infiltrating cells from lung tissues were enumerated, stained with
yzed by flow cytometry after gating on forward and side scatter. Mean
hi1) CD4 (B) and CD8 (D) T cells 6 SD were calculated from groups
unchallenged mice per time point (. . .n. . .).after R
with RS
d anal
(CD69
naivehan of BBG2Na-immunized animals (P , 0.05), indi-
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134 PLOTNICKY-GILQUIN ET AL.ating that clearance of virus was in fact most effective
n the former mice. Therefore, as the low level of virus
ene transcription following challenge in the lungs of
FIG. 6. Kinetics of Th1 (A, B) and Th2 (C, D, E, F) cytokine mRNA exp
ice for each time point were immunized with BBG2Na (—F—), FI-RS
mmunization, mice were challenged with RSV-A. On days 2, 5, 7, 9, an
xtracted and reverse-transcribed into cDNA. PCR amplified product
-actin-amplified products were calculated and results shown are mea
aseline levels for each cytokine (. . .n. . .).I-RSV-primed mice seemed to be sufficient to recall pmmunopathologic responses in these animals, the
bsence of immunopathology in BBG2Na-immunized
ice is unlikely to be explained by a higher sterilizing
in lung infiltrating cells upon RSV challenge. Groups of four to seven
– z ), or PBS (——) three times in Alhydrogel. Ten days after the last
stchallenge, lung infiltrating cells were isolated, and total mRNA was
analyzed by semiquantitative ELISA. OD405nm ratios of cytokines to
D of OD405nm ratios. Naive unchallenged mice were used to determineression
V (– z n
d 14 po
s were
ns 6 Srotection than in the FI-RSV group.
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135ABSENCE OF IMMUNOPATHOLOGY WITH RSV G FRAGMENTDISCUSSION
Major obstacles to vaccine development against RSV
nfection include induction of partial immunity and/or
evere immunopotentiation of RSV disease. In this com-
unication, we demonstrate that a recombinant RSV-A G
rotein fragment, which is highly immunogenic and pro-
ects rodents against prototype RSV A and B viruses
Power et al., 1997), does not prime for deleterious Th2-
ype anti-RSV pulmonary immunopathologic responses.
In our experiments, the primary anti-RSV immune re-
ponse in PBS-immunized mice was characterized by a
eak of activated CD81 T cells, which was first evident in
he MLN and then in the lungs, the detection of signifi-
ant levels of pulmonary IL-2 and IFN-g mRNAs, and the
bsence of enhanced Th2-type cytokine expression at
arly time points. These data are indicative of Th1-type
esponses, which is consistent with previous reports of
SV infection in adult humans and rodents (Graham et
l., 1993; Hussell et al., 1996; Anderson et al., 1994).
ctivated CD41 T cells were also detected, consistent
ith their role in the development of both cytotoxic and B
ymphocyte immune responses (for review see Swain,
991). Indeed, these cells may represent the major cel-
ular source of IL-2 mRNA. The detection of a significant
eak of IL-10 mRNA at day 9 (consistent with the work of
ussel et al., 1996), a cytokine that represses Th1-type
ellular immune responses (Fiorentino et al., 1991), sug-
ests active immunosuppression of the cytotoxic T cell
esponse in these animals.
Alternatively, the postchallenge anti-RSV immuno-
athologic responses in FI-RSV-immunized mice was
haracterized by a massive cellular infiltration of all lym-
hocyte subsets in MLN and a predominance of acti-
ated CD41 T lymphocytes and eosinophils in the lungs.
FIG. 7. Effects of BBG2Na, FI-RSV, and PBS immunizations on viral
ene expression in lung tissues 2 days postchallenge with RSV. The
resence of viral G mRNA in mouse lungs was analyzed by RT-PCR
LISA, as outlined under Materials and Methods. Results calculated
rom five or six animals per group represent the means 6 SD of
D405nm for the G mRNA relative to the OD405nm for the b-actin mRNA.
P , 0.05 calculated by the t test using null hypothesis.nterestingly, elevated expression of both Th1- (IFN-g, cL-2) and Th2-type (IL-4, IL-5, IL-10, IL-13) cytokine
RNAs was evident in lung infiltrates isolated from these
nimals, indicating that memory responses upon RSV
hallenge were not exclusively Th2 in nature. However,
he elevated Th2-type cytokine gene expression was
xclusive to the FI-RSV primed mice. This is consistent
ith mechanistic roles of IL-4, IL-5, and IL-10 in FI-RSV-
nd G-protein-induced enhanced pathology (Connors et
l., 1992, 1994; Hancock et al., 1996). Although absolute
evels appeared low, the most striking differences in
ytokine expression levels between FI-RSV-immunized
ice and the other groups related to IL-13 mRNA syn-
hesis, thereby suggesting a role for IL-13 in FI-RSV
nduced immunopathology. Elevated expression of IFN-g
nd IL-2 mRNAs suggests that these cytokines do not
xercise antagonistic roles in preventing enhanced pul-
onary immunopathology.
In striking contrast, mice immunized with BBG2Na
howed no evidence of Th2-type cytokine mRNA synthe-
is, T cell activation, cell infiltration, or inflammatory
esponses in the lungs during the 2 weeks following
ntranasal challenge. T and B cell infiltration did occur in
he MLN but it remained comparable to that of PBS-
mmunized/challenged mice. However, no activated
D81 T cells were identified consistent with the inability
f RSV G protein to induce a CD81 cytotoxic T cell
esponse (Johnson and Collins, 1988; Openshaw et al.,
990). These data indicate that BBG2Na priming influ-
nces the type of MLN infiltrating responses compared
ith mice undergoing primary infection. In addition, al-
hough their levels were relatively low compared to PBS-
mmunized/challenged mice, IL-2 and IFN-g mRNA ex-
ression was slightly increased in lung infiltrates during
he first week compared to expression in naive unchal-
enged mice. This is suggestive of a tendency toward a
h1-type response postchallenge in these animals. Over-
ll, our data indicate that Th2-type memory T cells or
ytokines were not recalled in lung tissues following RSV
hallenge of BBG2Na-primed mice. This is concordant
ith the previously reported cytokine analyses per-
ormed in BBG2Na-immunized mice, which demon-
trated the absence of IL-4, IL-5, and IgE recall re-
ponses in the serum following live viral challenge (Cor-
aia et al., 1997). Our data are in stark contrast to
revious work showing Th2-type RSV immunopathologic
esponse following prior immunization with native or
accinia virus-expressed RSV G protein (Vaux-Peretz et
l., 1992; Alwan et al., 1994; Hancock et al., 1996; Stott et
l., 1987). The switch from a predominantly Th2-like re-
ponse after immunization with BBG2Na toward a dis-
rete Th1-like profile following RSV-A challenge sug-
ests that the virus-induced Th1-like cytokine responses
upersede the preexisting BBG2Na-induced profiles. Al-
ernatively, the Th2-like responses induced following FI-
SV or native G protein priming might overwhelm the
hallenge RSV response.
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136 PLOTNICKY-GILQUIN ET AL.Recently, an overlapping domain (residues 193–203)
nd a T cell epitope (residues 184–198), which were
hown to be implicated in RSV enhanced pathology,
ere identified on the G protein (Sparer et al., 1998;
ebbey et al., 1998). This domain and T cell epitope map
ithin the G2Na fragment. However, our data indicate
hat these elements are insufficient in the context of
BG2Na to induce aberrant cellular infiltration in the
ungs postchallenge. Furthermore, in contrast to a previ-
us hypothesis (Graham et al., 1993) suggesting that
terilizing immunity may prevent or diminish the extent of
nhanced pathology, we did not find a correlation be-
ween the level of viral transcription in the lungs (and by
xtension the level of viral antigens) and the induction of
nhanced pathology. Indeed, our data suggest that
BG2Na-immunized mice had more viral antigen in their
ungs than FI-RSV-immunized mice. Therefore, as FI-RSV
rimed mice demonstrated extensive immunopathology
pon challenge, the absence of pathology in the BBG2Na
roup is unlikely to be due to insufficient viral antigens.
As BBG2Na is produced as a fusion protein in a
rokaryotic expression system, several hypotheses may
e drawn to explain the absence of RSV enhanced dis-
ase in BBG2Na-immunized/challenged mice. First,
BG2Na is nonglycosylated by virtue of its prokaryotic
rigin, suggesting the possibility that intracellular pro-
essing by antigen-presenting cells is altered relative to
he native G protein, thereby influencing the type of
mmune response generated. However, glycosylation
oes not seem to be a critical factor for the induction of
nhanced pathology since significant lung eosinophilia
as induced after RSV challenge in mice primed with a
ynthetic peptide coupled to KLH (Tebbey et al., 1998).
econd, the carrier protein properties of BB, coupled
ith its high affinity for serum albumin and its capacity to
xtend the in vivo half-life of its fusion partner (Makrides
t al., 1996; Nygren et al., 1991), suggest the likelihood
hat G2Na is presented to the immune system in a
ifferent manner and with different kinetics than the
ative G protein. Third, CD41 T cell clones generated by
mmunization with BBG2Na might be principally elicited
y BB, with fewer T cell clones specific for G2Na. In
ontrast, immunization with FI-RSV or the native G pro-
ein alone is likely to stimulate a greater number of
SV-specific T cell clones, which are recalled after live
SV challenge. Finally, memory T cells induced upon
mmunization with BBG2Na may fail to recognize the
ntigens provided by the viral challenge. Indeed, previ-
us experiments showed that, unlike live RSV, BBG2Na
dministered by the i.n. route in the presence of cholera
oxin subunit B stimulated IL-4 and IL-5 secretion in the
erum of BBG2Na-immunized mice (Corvaia et al., 1997).
eactivation of Th2-type T cells elicited by immunization
ith BBG2Na was thus possible but entirely dependent
pon appropriate stimulation. This stimulation was evi- wently not provided by the RSV challenge. These hypoth-
ses are currently under investigation.
Previous studies demonstrated the importance of the
riming on the disease-enhancing immune response
nd indicated that eliciting a Th2-type primary response
as critical for the induction of FI-RSV-like immunopa-
hology (Graham et al., 1993; Stott et al., 1987; Waris et al.,
997). Alternatively, our data with Alhydrogel adsorbed
BG2Na clearly indicate that induction of a Th2-type
esponse upon immunization does not necessarily imply
h2-type recall responses and immunopathology upon
SV challenge. This discrepancy opens the possibility of
xploiting BBG2Na, in comparison with FI-RSV, to identify
orrelates of RSV vaccine safety and/or postinfection
ulmonary pathology following vaccination, a key re-
uirement for clinical development of such vaccines in
eronegative infants. In view of the data presented above
nd previous reports (Brandt et al., 1997; Corvaia et al.,
997; Power et al., 1997), it is tempting to speculate that
nduction of strong protective humoral responses cou-
led with weak or absent virus-specific cellular re-
ponses might provide the safest profile for an RSV
accine. In conclusion, it is clear that the recombinant
himeric protein BBG2Na, comprising in part residues
30–230 of the RSV G protein, is a different immunolog-
cal entity than FI-RSV or native G protein.
MATERIALS AND METHODS
ene assembly, vector constructions, and expression
f BBG2Na
Gene assembly, vector constructions, expression, and
irst-step protein purification of BBG2Na were under-
aken as previously described (Murby et al., 1995;
guyen et al., 1994). Proteins were further purified to
omogeneity by reverse-phase high-performance liquid
hromatography. Protein purity and antigenicity were an-
lyzed by SDS–PAGE on 15% homogenous gels under
educing conditions and by Western blots using RSV-A-
pecific serum, respectively.
irus preparation
Respiratory syncytial virus subgroup A (Long strain)
as propagated in HEp-2 cells as previously described
Trudel et al., 1991; Power et al., 1997). Viruses were
arvested after 48–72 h by scraping attached cells into
he medium, centrifuging the suspension at 460 g for 15
in, and collecting the supernatant as the virus stock.
I-RSV was prepared as described by Prince et al. (1986),
xcept that it was not concentrated by centrifugation.
I-RSV was stored at 280°C until use.
ice
Specific pathogen-free female BALB/c mice, ages 6–9
eeks, were purchased from IFFA CREDO, l’Arbresle,
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137ABSENCE OF IMMUNOPATHOLOGY WITH RSV G FRAGMENTrance. They were fed mouse maintenance diet AO4
UAR, Villemoissin-sur-Orge, France) and given water ad
ibitum.
mmunization and challenge procedures
All mice were confirmed to be seronegative vis-a`-vis
SV-A before inclusion in the experiments as previously
escribed (Power et al., 1997). They were immunized on
ays 0, 14, and 24 by intraperitoneal (i.p.) injection of 200
l PBS solution alone or containing BBG2Na (20 mg) or
I-RSV (1/100e) in 20% Al(OH3) (Alhydrogel; vol/vol; Su-
erfos BioSector, Vedbaek, Denmark). Seroconversion
as determined 10 days following the last immunization.
ean RSV-A-specific serum antibody ELISA titers were
og10 5, 4, and ,2, in BBG2Na-, FI-RSV-A-, and PBS-
mmunized mice, respectively. Mice were challenged on
ay 35 by i.n. instillation of 105 or 106 tissue culture
nfectious doses50 RSV-A and sacrificed 2, 5, 7, 9, 12, and
4 days later.
reparation of cells from MLN and lungs
After cardiac puncture, residual blood was removed
rom lung tissues by perfusion of the circulatory system
ith PBS containing 10 U/ml heparin. Lungs and MLN
ere harvested. A small fragment of lung was quick-
rozen in liquid nitrogen for further RNA extraction.
ymph node cells were isolated by dissociation of MLN
n RPMI 1640 (Gibco, Cergy Pontoise, France) supple-
ented with 15% fetal calf serum. Lungs were minced
nd incubated for 30 min at 37°C in an enzymatic mixture
onsisting type VII collagenase (75 U/ml, Sigma, St.
uentin Fallavier, France), DNase I (50 U/ml, Boehringer
annheim Biochemica, Germany), and Dispase I (0.2
/ml, Boehringer Mannheim Biochemica). After careful
issociation in dounce homogenizers, cell suspensions
ere reincubated for 30 min at 37°C, passed through a
5-mm cell strainer (Becton Dickinson, Franklin Lakes,
J), and washed twice in RPMI 1640 with 15% fetal calf
erum. Total numbers of nucleated cells were enumer-
ted under light microscopy by the Trypan blue exclusion
ethod (.98% viability) before preparation for flow cy-
ometry and/or RNA extraction.
solation and enumeration of infiltrating eosinophils
Lung infiltrating cells were analyzed by forward and
ide scatter by flow cytometry (FACSvantage, Becton
ickinson, Erembodegem, Belgium) and large granular
ells were sorted. Cells were centrifuged on microscopic
lides (300 rpm for 3 min) (Cytospin 3, Shandon INC,
ittsburgh, PA) and stained by May-Gru¨nwald Giemsa
Sigma). An average of 200 total cells were counted per
lide to determine the percentage of eosinophils. The
otal number of lung infiltrating eosinophils per mouse
as calculated as follows: fraction of eosinophils (light
icroscopy) 3 fraction of large granular cells (FACS) 3 ootal number of nucleated cells isolated from lungs (light
icroscopy).
mmunofluorescence cell staining
One hundred microliters of cells was distributed into
-bottomed 96-well plates at 3 3 105/well and centri-
uged, and the pellets were washed in cold PBS. Cells
ere incubated at 4°C for 30 min with combinations of
luorescein, phycoerythrin, or tricolor-conjugated mono-
lonal antibodies to lymphocyte surface molecules CD3,
D4, CD8, CD69, CD11a/CD18 (Caltag, San Francisco,
A), TCRab (b chain), TCRgd, CD45R/B220 (Pharmingen
nc., San Diego, CA), and granulocytes (clone RB6-8C5,
altag), at previously determined optimal concentra-
ions. Cells were washed in cold PBS and fixed with 100
l/well of PBS–1% paraformaldehyde. The cells were
nalyzed for two or three color stains using a FACScan
Becton-Dickinson) with the Lysis II software program
fter debris and dead cells were removed by gating on
orward and side scatter. Results are expressed as
eans of the total number of stained cells (total number
f nucleated cells 3 percentage of cells stained with a
pecific cell surface marker) 6 SD obtained from parallel
xperiments including naive unchallenged mice and
ice immunized with BBG2Na, FI-RSV, or PBS and chal-
enged with RSV-A.
NA extraction
Lung infiltrating cells were centrifuged at 200 g for 10
in, quick-frozen in liquid nitrogen, and stored at 280°C
ntil RNA extraction. Total cellular RNA was purified by a
ethod derived from that of Chomczynski and Sacchi
1987). Briefly, cells were lysed in RNA-B (Bioprobe Sys-
ems, Montreuil-sous-Bois, France). RNA from 3 3 105
ells was extracted with chloroform for 5 min on ice.
rozen lung fragments were weighed and disrupted in 1
l RNA-B using a Dounce homogenizer. RNA was then
xtracted with chloroform from the equivalent of 1 mg
ung homogenate. After centrifugation at 12,000 g for 15
in at 4°C, RNA in the aqueous phase was precipitated
ith 1 vol isopropanol and washed with 75% ethanol. The
NA pellet was resuspended in 100 ml diethylpyrocar-
onate-treated water; 2.5 ml was subjected to PCR anal-
sis to exclude genomic DNA contamination. An addi-
ional precipitation of the RNA was performed with 2 vol
f ethanol in the presence of 0.2 M NaCl. Average yields
ere approximately 1 mg total RNA. Purified RNA was
tored at 280°C until reverse transcribed.
rimers and probes
Primers and probes were synthesized by Genset SA
Paris, France) and are shown in Table 1. Sequences
ere obtained from Clontech Laboratories (Ozyme,
aris, France) or Stratagene (LaJolla, CA) or were based
n published sequences. Oligonucleotides specific for
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138 PLOTNICKY-GILQUIN ET AL.he RSV-A G gene were determined using the MacVector
oftware program (Oxford Molecular Group, Oxford, UK).
or PCR amplification, primer concentrations were 0.8
M for genomic DNA, IL-4, IL-5, and RSV-A G cDNAs and
mM for b-actin, IL-2, IL-10, IL-13, and IFN-g cDNAs.
roducts span intron–exon junctions, thereby ensuring a
ytokine mRNA-derived PCR product. In the semiquanti-
ative ELISA protocol, 59 biotinylated oligonucleotide
robes were 15 and 25 pmol/ml hybridization solution for
L-5 and IL-13, respectively, and 7.5 pmol/ml for all other
CR products.
T-PCR ELISA detection of mRNA
The isolated RNA was first reverse transcribed to
DNA with 1 mg oligo(dT)15 (Promega, Lyon, France) and
5 U AMV reverse transcriptase (Promega) in a final
olume of 35 ml, according to the manufacturer’s instruc-
ions. The cDNA library was then diluted twofold with
terile water and stored at 220°C until required. For
CRs, 2 ml of cDNA was added to 23 ml of standard PCR
uffer (Perkin–Elmer, Roissy, France) supplemented with
% LB broth and containing unlabeled dNTPs (200 mM
ach) plus 10 mM digoxigenin (DIG)-labeled dUTP
Boehringer Mannheim, Meylan, France) and 2.5 U of
mpliTaq Gold DNA polymerase (Perkin–Elmer). For
L-13, buffer conditions were Tris–HCl, pH 8.6, and 2.5
M MgCl2. The sequence of PCR amplification con-
isted of a first step at 95°C for 10 min, followed by 30
T
Oligonucleotide Sequences and Reaction Conditi
Gene Primer sequence
enomic
DNA
(1) 59-GTGGGCCGCTCTAGGCACCAA-39a
(2) 59-CTCTTTGATGTCACGCACGATTTC-39a
-Actin (1) 59-TGTGATGGTGGGAATGGGTCAG-39b
(2) 59-TTTGATGTCACGCACGATTTCC-39b
(1
L-2 (1) 59-GTCAACAGCGCACCCACTTCAAGC-39b
(2) 59-GCTTGTTGAGATGATGCTTTGACA-39b
(2
L-4 (1) 59-CCAGCTAGTTGTCATCCTGCTCTTCTTTCTCG-39a
(2) 59-CAGTGATGTGGACTTGGACTCATTCATGGTGC-39a
(1
L-5 (1) 59-ATGAGAAGGATGCTTCTGCACTTGA-39a
(2) 59-GTCACCATGGAGCAGCTCAGCC-39a
(2
L-10 (1) 59-GTGAAGACTTTCTTTCAAACAAAG-39b
(2) 59-CTGCTCCACTGCCTTGCTCTTATT-39b
(1
L-13 (1) 59-TCTCCCCAGCAAAGTCTGAT-39c
(2) 59-CTGGATTCCCTGACCAACAT-39c
(2
FN-g (1) 59-TACTGCCACGGCACAGTCATTGAA-39b
(2) 59-GCAGCGACTCCTTTTCCGCTTCCT-39b
(2
SV-A G (1) 59-CTTCAACAACACCAGGAGTC-39e
(2) 59-TGGTGTTGATGGTTGGCTC-39e
(1
a Sequences obtained from Clonetech.
b Sequences obtained from Stratagene.
c Sequences obtained from Warris et al., 1996.
d Sequences obtained from Montgomery et al., 1991.
e Sequences determined according to Wertz et al., 1985.ycles at 15 s at 95°C, 1 min at 60°C (55°C for RSV- wpecific primers), and 1 min at 72°C. The amplification
as terminated by a final extension step at 72°C for 7
in. Amplifications were performed in a Perkin–Elmer
600 or 9700 thermal cycler. b-Actin cDNA was amplified
s an internal control for variations in RNA extractions
nd cDNA synthesis. b-Actin cDNAs were of comparable
evels for all samples analyzed. The linear range of sig-
al strength was determined by performing titration for
DNA and cycle numbers to obtain nonsaturated PCRs
or each amplification. Negative and positive controls
onsisted of amplifications with water instead of cDNA
nd with saturating amounts of gel-purified specific PCR
roduct, respectively.
PCR products were first checked for appropriate size
n 2% agarose gels containing ethidium bromide. Subse-
uently, amplicon identities were confirmed and quanti-
ied by a semiquantitative ELISA protocol (Boehringer
annheim). Briefly, 2.5 ml of the amplified product (pure
r 1:10 or 1:50 dilutions) was incubated with 20 ml of
enaturation solution for 10 min, followed by addition of
25 ml of hybridization buffer containing the specific
iotinylated oligonucleotide probe. Controls included the
egative and positive PCR samples, a control DIG-la-
eled product, and a specific probe provided by the
anufacturer. Two hundred microliters of the solution
as distributed in a multiwell streptavidin-coated plate
nd incubated under agitation at 37°C for 3 h. The plate
as then washed and any bound product was detected
ed in mRNA cDNA Detection by RT-PCR–ELISA
Probe sequence
PCR
product
size
(bp)
Number
of PCR
cycles
— 540 35
GCAAGAGAGGTACTCT-39d 514 26
TTCATCTTCTAGGCACTG-39c 450 30
CGGAGATGGATGTGCCAAACTC-39b 357 30
CCTTCCATTGCCCACTCTGTAC-39b 425 30
TGCAGGACTTTAAGGGTTACTTGGGTT-39a 274 30
GTCTCCCAGCCTCCCCGATA-39c 262 30
GGACCTGTGGGTTGTTGACCTCAAACTTGGC-39a 405 30
CAACAATCCAACCTGCTGGG-39e 369 35ABLE 1
ons Us
) 59-(b)A
) 59-(b)G
) 59-(b)A
) 59-(b)G
) 59-(b)A
) 59-(b)G
) 59-(b)T
) 59-(b)Gith peroxidase-conjugated anti-DIG antibodies in a
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139ABSENCE OF IMMUNOPATHOLOGY WITH RSV G FRAGMENTtandard colorimetric reaction using 29-azino-di[3-ethyl-
enthiazoline sulfonic acid] substrate. The OD405nm was
ecorded. Under these conditions, the OD405nm was di-
ectly proportional to the level of target PCR product,
hich was subsequently normalized relative to OD405nm
etected for b-actin mRNA.
tatistical analyses
Statistical analyses were done using the multirange
nd t test of the Statgraphic software program (Manugis-
ics, Rockville, MD).
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